A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia

References

• Dubois RW, Pinto LA, Bernal M, et al. Benefits of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced complications: a systematic review of the literature. Support Cancer Ther. 2004;2(1):34–41.
   PubMedGoogle Scholar
• Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist. 2009;14(S1):43–56.
   PubMed Web of Science ®Google Scholar
• Cairo MS. Dose reductions and delays: limitations of myelosuppressive chemotherapy. Oncology. 2000;14(9 Suppl 8):21–31.
   PubMedGoogle Scholar
• O’Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(7):926–957.
   PubMed Web of Science ®Google Scholar
• Hong H, Xiao W, Lazarus HM, et al. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016;127(4):496–502.
   PubMed Web of Science ®Google Scholar
• Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600–613.
   PubMed Web of Science ®Google Scholar
• Chawla SP, Staddon A, Hendifar A, et al. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide [journal article]. BMC Cancer. 2013;13(1):121.
   PubMed Web of Science ®Google Scholar
• Iuliano F, Iuliano E, Perricelli A, et al. Low doses of eltrombopag are safe and effective in the prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT). Blood. 2016;128((22):4926–4926.
   Web of Science ®Google Scholar
• Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, et al. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin. 2010;26(10):2339–2346.
   PubMed Web of Science ®Google Scholar
• Winer ES, Safran H, Karaszewska B, et al. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med. 2015;4(1):16–26.
   PubMed Web of Science ®Google Scholar
• Marotta S, Marano L, Ricci P, et al. Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant. 2019;54(8):1346–1353. Aug(
   PubMed Web of Science ®Google Scholar
• Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;5(1):e34–e43.
   PubMed Web of Science ®Google Scholar
• Kalota A, Selak MA, Garcia-Cid LA, et al. Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival. PloS One. 2015;10(4):e0126691.
   PubMed Web of Science ®Google Scholar
• Sugita M, Kalota A, Gewirtz AM, et al. Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression. Leukemia. 2013;27(5):1207–1210.
   PubMed Web of Science ®Google Scholar
• Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120(2):386–394.
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, Kirchner J, Aivado M, et al. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leukemia Res. 2010;34(9):1224–1231.
   PubMed Web of Science ®Google Scholar
• Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009;114(18):3899–3908.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Sockel K, Schonefeldt C, et al. Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia. Haematologica. 2014;99(12):e247–8.
   PubMed Web of Science ®Google Scholar
• Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132(25):2629–2638.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227–2236.
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–19.
   PubMed Web of Science ®Google Scholar
• Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550.
   PubMed Web of Science ®Google Scholar
• Cole S, Benard L, Carvajal LA, et al. Pre-clinical modeling of concomitant therapy with azacytidine and eltrombopag in MDS/AML. Blood. 2017;130(1):2950–2950.
   Google Scholar
• Itzykson R, Lambert J, Barbieri D, et al. A phase II trial of eltrombopag in chronic myelomonocytic leukemia (CMML) with thrombocytopenia. Blood. 2017;130(Suppl 1):4266–4266.
   Google Scholar
• Mukherjee S, Elson P, Bogati S, et al. A single arm, phase II study of eltrombopag to enhance platelet count recovery in older patients with acute myeloid leukemia undergoing remission induction therapy. Blood. 2016;128((22):447–447.
   Web of Science ®Google Scholar
• Frey N, Jang JH, Szer J, et al. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019;6(3):e122–e131.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Wong RS, Verma A, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015;2(10):e417–e426.
   PubMed Web of Science ®Google Scholar